NCT05172700 2024-12-18Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerEli Lilly and CompanyApproved for marketing
NCT01196208 2020-09-21A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001Seagen Inc.No longer available